Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $13.63
  • 50 Day Moving Average: $10.83
  • 200 Day Moving Average: $8.29
  • 52-Week Range: $4.37 - $13.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.13
  • P/E Growth: -5.05
  • Market Cap: $2.61B
  • Outstanding Shares: 192,713,000
  • Beta: 1.92
Profitability:
  • Net Margins: -35.00%
  • Return on Assets: -10.26%
Debt:
  • Debt-to-Equity Ratio: -12.32%
  • Current Ratio: 3.05%
  • Quick Ratio: 3.04%
Additional Links:
Companies Related to Ariad Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $9.29 (31.32% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetDetails
7/31/2016Cowen and CompanyReiterated RatingOutperform$10.00View Rating Details
7/29/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details
7/29/2016Barclays PLCBoost Price TargetUnderweight$8.00 -> $9.00View Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details
6/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
5/24/2016William BlairReiterated RatingBuy$10.00View Rating Details
3/11/2016JPMorgan Chase & Co.Reiterated RatingOutperform$11.00 -> $9.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$7.00 -> $5.00View Rating Details
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details
12/11/2014Credit Suisse Group AGDowngradeNeutral -> Underperform$8.00 -> $6.00View Rating Details
11/6/2014Chardan CapitalReiterated RatingNeutralView Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20162($0.22)($0.21)($0.22)
Q4 20162($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 71.99%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateHeadline
News IconAriad Shares Rise Amid Speculation of Potential Buyout (NASDAQ:ARIA)
myhealthbowl.com - September 24 at 3:31 PM
News IconEye Catching Insider Trading: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 24 at 8:54 AM
finance.yahoo.com logoHow trader is showing support for Ariad (NASDAQ:ARIA)
finance.yahoo.com - September 23 at 8:24 AM
News IconTime To Put On The Watch List? - Nektar Therapeutics (NASDAQ:NKTR), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 22 at 3:32 PM
investopedia.com logoAriad Receives Interest as a Buyout Candidate (NASDAQ:ARIA)
www.investopedia.com - September 22 at 3:32 PM
News IconBiotech news that matter for investors: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Conatus Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 21 at 4:29 PM
News IconAriad Pharmaceuticals Inc. (NASDAQ:ARIA) To Report September 2016 Results - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 21 at 4:29 PM
marketwatch.com logo4 health-care stocks to watch (NASDAQ:ARIA)
www.marketwatch.com - September 21 at 4:29 PM
News IconHC Stocks in Top Row! Ariad Pharmaceuticals, Inc. (ARIA), Northwest Biotherapeutics, Inc (NASDAQ:NWBO) - share market updates (press release) (NASDAQ:ARIA)
sharemarketupdates.com - September 21 at 8:49 AM
bloomberg.com logoAriad Shares Rise Amid Speculation of Potential Buyout - Bloomberg (NASDAQ:ARIA)
www.bloomberg.com - September 21 at 8:49 AM
thestreet.com logoAriad Pharma (ARIA) Stock Surged Today on Takeover Speculation (NASDAQ:ARIA)
www.thestreet.com - September 21 at 8:49 AM
News IconTrader's Buzzer: PayPal Holdings, Inc. (NASDAQ:PYPL), ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Newburgh Press (NASDAQ:ARIA)
newburghpress.com - September 20 at 3:33 PM
News IconBiotech Stocks Worth a Closer Look: Radius Health, Inc. (NASDAQ:RDUS), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 20 at 3:33 PM
News IconHC Stocks Reports Analysis! Ariad Pharmaceuticals, Inc. (ARIA), Abbott Laboratories (NYSE:ABT) - share market updates (press release) (NASDAQ:ARIA)
sharemarketupdates.com - September 20 at 3:33 PM
News IconOverbuying Alert on: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - Post Registrar (NASDAQ:ARIA)
postregistrar.com - September 20 at 3:33 PM
finance.yahoo.com logoAriad Shares Rise Amid Speculation of Buyout Target Potential (NASDAQ:ARIA)
finance.yahoo.com - September 20 at 3:33 PM
marketrealist.com logoHow Ionis Pharmaceuticals’ Valuation Compares to Its Peers (NASDAQ:ARIA)
marketrealist.com - September 20 at 3:33 PM
News IconAriad Pharmaceuticals Inc. (ARIA) Insider Sells $696,398.37 in Stock (NASDAQ:ARIA)
www.bioportfolio.com - September 19 at 4:29 PM
thestreet.com logoAriad Pharmaceuticals (ARIA) Stock Is Monday's 'Chart of the Day' (NASDAQ:ARIA)
www.thestreet.com - September 19 at 4:29 PM
News IconHC Stocks News! Ariad Pharmaceuticals, Inc. (ARIA), Northwest Biotherapeutics, Inc (NASDAQ:NWBO) - share market updates (press release) (NASDAQ:ARIA)
sharemarketupdates.com - September 16 at 3:35 PM
finance.yahoo.com logoPut seller betting Ariad will hold gains (NASDAQ:ARIA)
finance.yahoo.com - September 16 at 12:15 PM
streetinsider.com logoARIAD Pharma (ARIA) to Make Several Iclusig Presentation at John Goldman Conference - StreetInsider.com (NASDAQ:ARIA)
www.streetinsider.com - September 15 at 8:42 PM
forbes.com logoARIAD Pharmaceuticals Reaches Analyst Target Price - Forbes (NASDAQ:ARIA)
www.forbes.com - September 15 at 8:42 PM
mysmartrend.com logoAriad Pharmaceuticals Shares Up 36.5% Since SmarTrend's Buy Recommendation (ARIA) (NASDAQ:ARIA)
www.mysmartrend.com - September 15 at 12:27 PM
businesswire.com logoARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia (NASDAQ:ARIA)
www.businesswire.com - September 15 at 12:27 PM
forbes.com logoARIAD Pharmaceuticals Reaches Analyst Target Price (NASDAQ:ARIA)
www.forbes.com - September 15 at 12:27 PM
News IconShares Climbing Higher Session: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Post News (NASDAQ:ARIA)
www.kentuckypostnews.com - September 14 at 3:34 PM
News IconShares Holding Above Moving Averages: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Post News (NASDAQ:ARIA)
www.kentuckypostnews.com - September 14 at 3:34 PM
News IconAriad Pharmaceuticals, Inc.(NASDAQ:ARIA) Downward Trend - Live Trading News (NASDAQ:ARIA)
www.livetradingnews.com - September 14 at 3:34 PM
finance.yahoo.com logoAriad Pharmaceuticals Leading Biotechs Higher (NASDAQ:ARIA)
finance.yahoo.com - September 14 at 3:34 PM
News IconAnalysts Valuations For Two Stocks: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), FireEye Inc (NASDAQ:FEYE) - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 13 at 8:23 AM
News IconHot Biotech Stocks Recap: CytRx Corporation (NASDAQ:CYTR), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 13 at 8:23 AM
finance.yahoo.com logoLast-minute call buyers pile into Ariad (NASDAQ:ARIA)
finance.yahoo.com - September 12 at 3:32 PM
benzinga.com logoWatch These 7 Huge Call Purchases In Monday Trade - Benzinga (NASDAQ:ARIA)
www.benzinga.com - September 12 at 8:22 AM
News IconHC Stocks Review= Ariad Pharmaceuticals, Inc. (ARIA), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NASDAQ:ARIA)
sharemarketupdates.com - September 12 at 8:22 AM
News IconExperts Views on Investment Luring Stocks- Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Synergy Pharmaceuticals, Inc ... - Seneca Globe (NASDAQ:ARIA)
www.senecaglobe.com - September 10 at 3:31 PM
News IconStocks Focus in Frontline Brokers- Ariad Pharmaceuticals Inc ... - Seneca Globe (NASDAQ:ARIA)
www.senecaglobe.com - September 9 at 3:33 PM
News IconBiotech news that matter for investors: Ariad Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 8 at 3:31 PM
News IconTrending Biotechnology Stocks Analyst Review: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Peregrine ... - Post Registrar (NASDAQ:ARIA)
postregistrar.com - September 7 at 3:34 PM
News IconTrending Biotechnology Stocks Analyst Review: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Peregrine ... - Post Registrar (NASDAQ:ARIA)
postregistrar.com - September 7 at 3:34 PM
capitalcube.com logoETF’s with exposure to ARIAD Pharmaceuticals, Inc. : September 7, 2016 (NASDAQ:ARIA)
www.capitalcube.com - September 7 at 12:40 PM
fool.com logoThis Expected News Sent PDL BioPharma Inc. Down 17% in August (NASDAQ:ARIA)
www.fool.com - September 7 at 12:40 PM
marketrealist.com logoIncyte’s Profitability Improves, Allowing for Revised Guidance (NASDAQ:ARIA)
marketrealist.com - September 5 at 3:34 PM
marketrealist.com logoIncyte’s Profitability Improves, Allowing for Revised Guidance (NASDAQ:ARIA)
marketrealist.com - September 5 at 3:34 PM
News IconAnalysts Valuations For Two Stocks: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Cloud Peak Energy Inc. (NYSE:CLD) - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 5 at 8:25 AM
News IconHC Stocks Assessment- Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) (NASDAQ:ARIA)
sharemarketupdates.com - September 3 at 8:25 AM
News IconAnalysts Valuations For Two Stocks: Hain Celestial Group Inc (NASDAQ:HAIN), Ariad Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 2 at 3:35 PM
News IconHot Biotech Stocks Recap: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Threshold Pharmaceuticals Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ARIA)
voiceregistrar.com - September 2 at 3:35 PM
marketrealist.com logoIs Incyte Hurt by Having Only One FDA-Approved Drug? (NASDAQ:ARIA)
marketrealist.com - September 2 at 3:35 PM
marketexclusive.com logoAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) Puts Brigatinib Ball In FDA's Court - Market Exclusive (NASDAQ:ARIA)
marketexclusive.com - September 1 at 11:59 AM

Social

Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff